Private company

Lomond Therapeutics Holdings, Inc.

Lomond Therapeutics Holdings, Inc. is an American pharmaceutical preparations company based in Dover.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersDover, Delaware1
  • Incorporated inDE2
  • Business addressC/O Lomond Therapeutics Holdings, Inc., 8 The Green Ste 8490, Dover, De 199012
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We were co-founded by OrbiMed Advisors LLC, or OrbiMed, Torrey Pines Investment LLC, or Torrey Pines, and Dr. John C. Byrd.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456-$24.5M in 2025+49950% since 2022
-$30.0M-$20.0M-$10.0M02022: -$48.9K-$48.9K20222023: -$9.8M-$9.8M2023+19851%2024: -$16.3M-$16.3M2024+67%2025: -$24.5M-$24.5M2025+50%
Net income456-$23.5M in 2025+48052% since 2022
-$30.0M-$20.0M-$10.0M02022: -$48.9K-$48.9K20222023: -$9.9M-$9.9M2023+20243%2024: -$17.1M-$17.1M2024+72%2025: -$23.5M-$23.5M2025+38%
Fiscal year202120222023202420252026
Research and development$9.7M5$14.3M6$20.3M6
Operating expenses$9.8M5$16.3M6$24.5M6
Operating income-$48.9K4-$9.8M5-$16.3M6-$24.5M6
Income before tax$17.1M6$23.5M6
Net income-$48.9K4-$9.9M5-$17.1M6-$23.5M6
Earnings per share-$0.014-$13.105-$3.306-$0.756
Earnings per share (diluted)-$0.014-$13.105-$3.306-$0.756
Shares (weighted, basic)5.0M shares4759.0K shares55.2M shares631.5M shares6
Shares (weighted, diluted)5.0M shares4759.0K shares55.2M shares631.5M shares6

Compare Lomond Therapeutics Holdings, Inc. with another company

Corporate structure

Lomond Therapeutics Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Lomond Therapeutics Holdings, Inc.

  • James E. Flynn Filed SCHEDULE 13G/A on Lomond Therapeutics Holdings, Inc., latest Nov 13, 2025 (2 filings since Nov 8, 2024)
  • Qatar Investment Authority Filed SCHEDULE 13G on Lomond Therapeutics Holdings, Inc., latest Mar 26, 2025
  • Ian Seth Jacobs Filed SCHEDULE 13G/A on Lomond Therapeutics Holdings, Inc., latest Feb 14, 2025 (2 filings since Feb 13, 2023)
  • Mark N. Tompkins Filed SCHEDULE 13G/A on Lomond Therapeutics Holdings, Inc., latest Feb 14, 2025 (2 filings since Feb 10, 2023)
  • Yosemite Fund I, L.P. Filed SCHEDULE 13G on Lomond Therapeutics Holdings, Inc., latest Jan 31, 2025
  • Eilean Therapeutics, LLC Filed SC 13D on Lomond Therapeutics Holdings, Inc., latest Nov 8, 2024
  • John B. Berding Filed SC 13G on Lomond Therapeutics Holdings, Inc., latest Nov 8, 2024
  • ORBIMED ADVISORS LLC Filed SC 13D on Lomond Therapeutics Holdings, Inc., latest Nov 8, 2024
  • S. Craig Lindner Filed SC 13G on Lomond Therapeutics Holdings, Inc., latest Nov 8, 2024
  • TPAV, LLC Filed SC 13D on Lomond Therapeutics Holdings, Inc., latest Nov 8, 2024
  • Lomond Therapeutics Holdings, Inc. Dover, Delaware

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Lomond Therapeutics Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$13.2M6 Dec 31, 2025$28.4M6 Dec 31, 2024−53.5%
Marketable securities, current$11.2M6 Dec 31, 2025

Properties, in its own words

We neither own nor lease any real property. The address of our principal office is that of our registered agent at 8 The Green Ste 8490, Dover, Delaware 19901.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led Lomond Therapeutics Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Iain D. Dukes2024

Chair

  1. Iain D. Dukes2024

President

  1. Nikolay Savchuk2024

Chief operating officer

  1. Nikolay Savchuk2024
2025
Board members and other officers (2)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorEddie Rodriguez named Feb 11, 202514

Former names

  • Venetian-1 Acquisition Corp.Dec 21, 2021 to Oct 28, 20242

Timeline

  1. Jan 13, 20268-K Ended a material agreement15
  2. Jan 13, 20268-K Entered a material agreement16
  3. Jun 20, 20258-K Regulation FD disclosure17
  4. Mar 28, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure18
  5. Feb 20, 20258-K Entered a material agreement19
  6. Jan 30, 20258-K Entered a material agreement; Unregistered sale of shares20
  7. Nov 22, 20248-K Financial statements and exhibits21
  8. Nov 7, 20248-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares22
  9. Nov 5, 2024New chief executive Iain D. Dukes becomes CEO11
  10. Jul 28, 20228-K Change of auditor23
  11. Jul 19, 20228-K Change of auditor24

Filings

72 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 10 major events, 14 insider forms, 13 large holders, 2 private raises, 15 other. The latest 20:

  1. Jul 10, 202615-12G EDGAR
  2. Jul 10, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  3. Jul 10, 2026RW WITHDRAWAL REQUEST EDGAR
  4. May 15, 202610-Q QUARTERLY REPORT EDGAR
  5. Apr 15, 202610-K ANNUAL REPORT EDGAR
  6. Mar 31, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
  7. Jan 13, 20268-K CURRENT REPORT EDGAR
  8. Jan 13, 20268-K CURRENT REPORT EDGAR
  9. Nov 14, 202510-Q QUARTERLY REPORT EDGAR
  10. Nov 13, 2025SCHEDULE 13G/A EDGAR
  11. Aug 14, 202510-Q QUARTERLY REPORT EDGAR
  12. Aug 1, 2025S-1/A AMENDMENT NO. 4 TO FORM S-1 EDGAR
  13. Jun 20, 20258-K CURRENT REPORT EDGAR
  14. Jun 18, 2025S-1/A AMENDMENT NO. 3 TO FORM S-1 EDGAR
  15. May 20, 202510-Q QUARTERLY REPORT EDGAR
  16. May 15, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  17. Apr 15, 202510-K ANNUAL REPORT EDGAR
  18. Apr 1, 2025NT 10-K NOTIFICATION OF LATE FILING EDGAR
  19. Mar 28, 20258-K CURRENT REPORT EDGAR
  20. Mar 26, 2025SCHEDULE 13G EDGAR

The 72 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 1, 2024Raised $53.9 million in a private offering of equity Form D: $63.9 million offered in all Form D

SEC filer profile

How Lomond Therapeutics Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLomond Therapeutics Holdings, Inc.1
  • CIK0001900520
  • Employer ID (EIN)87-29595753
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressC/O Lomond Therapeutics Holdings, Inc., 8 The Green Ste 8490, Dover, DE 199011
  • Phone561 464 28411
  • Shares outstanding32,198,214 as of May 14, 20269
  • Public float$0 as of Jun 30, 20256
  • AuditorEisnerAmper LLP, Philadelphia, Pennsylvania PCAOB ID 274; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceDec 21, 20211
  • Filings73 in all: 10-Q (13), 8-K (9), 3 (8), 4 (6), SC 13G (6), 10-K (5), S-1/A (4), SC 13D (3)1
    All 23 form types

    SCHEDULE 13G/A (3), NT 10-K (2), SCHEDULE 13G (2), 10-12G (1), 15-12G (1), 8-K/A (1), D (1), D/A (1), NT 10-Q (1), RW (1), S-1 (1), S-8 (1), S-8 POS (1), SC 14F1 (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) May 15, 2026
    Latest 8-K (8-K) Jan 13, 2026

Risk factors and legal proceedings

The risks Lomond Therapeutics Holdings, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 75 risks under these headings, as written.3

  • Risks Related to Our Business, Financial Position and Capital Requirements
  • We are very early in our development efforts, have a limited operating history, have not conducted any late-stage clinical trials, have no products approved for commercial sale and have not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and viability.
  • There is no guarantee that the related party Eil license agreement or the related party Bala license agreement will positively affect our business, results of operations or prospects.
  • The termination of our Bala License Agreement may adversely impact our business, results of operations, financial performance, and reputation.
  • We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future.
  • Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve in a timely manner our objectives relating to the discovery, development and commercialization of our product candidates and development programs.
  • In the future, we will need substantial additional funding to complete the development and, if approved, any commercialization of product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.
  • Raising additional capital may cause dilution to our stockholders restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Risks Related to the Discovery, Research and Development of Product Candidates
  • We are very early in our development efforts for and are substantially dependent on our FLT3/IRAK4 and BCL-2 inhibitor programs. If we are unable to advance lomonitinib, our lead product candidate from the FLT3/IRAK4 program, or lonitoclax, our lead product candidate from the BCL-2 inhibitor program licensed from Eil through preclinical and clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.
  • In addition to our lead candidates, lomonitinib and lonitoclax, our business depends in part upon discovering, licensing or acquiring, developing and commercializing product candidates from other research programs, which may fail in development or suffer delays that adversely affect their commercial viability.
  • The deployment of artificial intelligence in our efforts to discover and develop product candidates, could adversely affect our business, reputation, or financial results.
The other 65 risks
  • We have only conducted preclinical studies and early clinical trials to date, and the outcome of preclinical testing and early clinical trials may not be predictive of the success of subsequent clinical trials, including in respect of demonstrating consistent or adequate efficacy and safety.
  • The design or our execution of our future clinical trials may not support marketing approval.
  • We have limited experience as a company in conducting clinical trials.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • Interim, topline and preliminary data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs.
  • If we encounter difficulties enrolling study subjects in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected.
  • Changes in methods of product candidate formulation may result in additional costs or delay.
  • Certain of our assets have been exclusively licensed for use within the Russian Federation. We are subject to geopolitical risks related to doing business in the Russian Federation.
  • Risks Related to the Manufacturing, Commercialization and Marketing of Product Candidates
  • We have never commercialized a product candidate as a company before and currently lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.
  • The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production, which may delay or prevent our ability to provide adequate supply of product candidates for clinical trials or our products for patients, if approved.
  • The market opportunities for any product candidates we develop, if approved, may be limited to certain smaller patient subsets and may be smaller than we estimate them to be.
  • Product candidates, if approved, may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
  • Lomonitinib, our licensed product candidates, including lonitoclax, and any product candidates we develop, license or acquire may become subject to unfavorable third-party coverage and reimbursement practices.
  • Downward pressure on healthcare costs may negatively affect the coverage and pricing of product candidates.
  • A variety of risks associated with marketing product candidates internationally could materially adversely affect our business.
  • Risks Related to Regulatory Approval Process and Other Healthcare Compliance Matters
  • We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize product candidates.
  • We may develop our current or future product candidates in combination with other therapies, which would expose us to additional risks.
  • The FDA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
  • Obtaining and maintaining regulatory approval of product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of product candidates in other jurisdictions.
  • Even if product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
  • The FDA and other comparable foreign regulatory agencies actively enforce the laws and regulations governing advertising and promotion, including those prohibiting the promotion of off-label uses.
  • If we are required by the FDA or other comparable foreign regulatory authority to obtain approval of a companion diagnostic test in connection with approval of any product candidates or a group of therapeutic products, and we do not obtain or we face delays in developing and obtaining approval of a diagnostic test, we will not be able to commercialize the product candidate and our ability to generate revenue will be materially impaired.
  • Even if we seek and receive accelerated approval from the FDA or other comparable foreign regulatory authorities, the FDA or such other comparable foreign regulatory authorities may seek to withdraw accelerated approval in certain circumstances.
  • We may seek Fast Track designation from the FDA for one or more product candidates. Even if one or more product candidates receive Fast Track designation, we may be unable to obtain or maintain the benefits associated with the Fast Track designation.
  • A Breakthrough Therapy designation by the FDA, even if granted for any product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that product candidates will receive marketing approval.
  • We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for product candidates and, even if we do, that exclusivity may not prevent the FDA or other comparable foreign regulatory authorities, from approving competing products.
  • We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
  • Inadequate funding for the FDA and other U.S. government agencies or other comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • We and our third-party business partners may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could each have a material and adverse impact on us.
  • Any of our employees that we may hire, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business
  • Our success is highly dependent on our ability to attract, hire and retain highly skilled executive officers, and we rely and will continue to rely on our services agreement with Abet Solutions.
  • We are highly dependent on the services of Dr. Iain Dukes and Dr. Nikolay Savchuk.
  • Certain of our officers may have actual or potential conflicts of interest because of their equity interests in or positions with other entities.
  • We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.
  • Our management has limited experience in operating a public company.
  • Requirements associated with being a public company will increase our costs significantly, as well as divert significant company resources and management attention.
  • Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or collaborators, may fail or suffer actual or suspected security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations, and potentially significant delays in our delivery to market.
  • Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.
  • The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly, which will make our future results difficult to predict and may cause our results to fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
  • We may not be able to utilize a significant portion of our net operating loss carryforwards.
  • Comprehensive tax reform legislation could adversely affect our business and financial condition.
  • Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.
  • Risks Related to Intellectual Property
  • We depend on intellectual property licensed from related parties, like Eil and Bala, the termination of which could result in the loss of significant rights, which would harm our business.
  • If we and our licensors and collaborators, if any, are unable to obtain and maintain sufficient patent and other intellectual property protection for product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any of our current or future product candidates.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
  • Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
  • We may not be successful in obtaining or maintaining necessary rights to product candidates through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our patents or our licensors’ patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or our licensors’ patents could be found invalid or unenforceable if challenged in court.
  • Intellectual property litigation could cause us to spend substantial resources, distract our personnel from their normal responsibilities and subject us to significant uncertainties.
  • Intellectual property litigation may lead to unfavorable publicity that harms our reputation and business.
  • Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
  • Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect product candidates.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Patent terms may be inadequate to protect our competitive position on product candidates for an adequate amount of time.
  • If we or our licensors do not obtain patent term extension for product candidates, our business may be materially harmed.
  • We and our licensors may not be able to protect intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

Legal proceedings

From time to time, we may be involved in various claims and legal actions arising in the ordinary course of business. As of December 31, 2025, we were not involved in any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34